Reirradiation Options for Previously Irradiated Prostate cancer (RO-PIP): Feasibility study investigating toxicity outcomes following reirradiation with stereotactic body radiotherapy (SBRT) versus high-dose-rate brachytherapy (HDR-BT)
Name:
36351720.pdf
Size:
2.522Mb
Format:
PDF
Description:
Identified with Open Access button
Authors
Zhong, J.Brown, S.
Serra, Maria
Shuttleworth, P.
Bownes, P.
Thompson, C.
Reed, Rachel
Reeves, Kimberley
Dubec, Michael
McHugh, Damien
Eccles, Cynthia L
Chuter, Robert
Tsang, Y. M.
Taylor, N. J.
West, Catharine M L
Buckley, D.
Scarsbrook, A.
Choudhury, Ananya
Hoskin, Peter J
Henry, A.
Affiliation
Leeds Institute of Medical Research, University of Leeds, Leeds, UKIssue Date
2022
Metadata
Show full item recordAbstract
Introduction: Radiotherapy is the most common curative treatment for non-metastatic prostate cancer; however, up to 13% of patients will develop local recurrence within 10 years. Patients can undergo further and potentially curative treatment including salvage surgery, brachytherapy (BT), external beam radiotherapy, high-intensity focused ultrasound and cryotherapy. Systematic review shows that high-dose-rate (HDR) BT and stereotactic body radiotherapy (SBRT) have the best outcomes in terms of biochemical control and lowest side effects. The reirradiation options for previously irradiated prostate cancer (RO-PIP) trial aims to determine the feasibility of recruitment to a trial randomising patients to salvage HDR-BT or SBRT and provide prospective data on patient recorded toxicity outcomes that will inform a future phase III trial. Methods and analysis: The primary endpoint of the RO-PIP feasibility study is to evaluate the patient recruitment potential over 2 years to a trial randomising to either SBRT or HDR-BT for patients who develop local recurrence of prostate cancer following previous radiation therapy. The aim is to recruit 60 patients across 3 sites over 2 years and randomise 1:1 to SBRT or HDR-BT. Secondary objectives include recording clinician and patient-reported outcome measures to evaluate treatment-related toxicity. In addition, the study aims to identify potential imaging, genomic and proteomic biomarkers that are predictive of toxicity and outcome based on hypoxia status, a prognostic marker of prostate cancer.Citation
Zhong J, Brown S, Serra M, Shuttleworth P, Bownes P, Thompson C, et al. Reirradiation Options for Previously Irradiated Prostate cancer (RO-PIP): Feasibility study investigating toxicity outcomes following reirradiation with stereotactic body radiotherapy (SBRT) versus high-dose-rate brachytherapy (HDR-BT). BMJ open. 2022 Nov 8;12(11):e068580. PubMed PMID: 36351720. Epub 2022/11/10. eng.Journal
BMJ OpenDOI
10.1136/bmjopen-2022-068580PubMed ID
36351720Additional Links
https://dx.doi.org/10.1136/bmjopen-2022-068580Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1136/bmjopen-2022-068580